NCT06973733|Not Yet Recruiting
Multimodal Database and Large Language Model for ARDS
Construction of ARDS Clinical Multimodal Database and ARDS-Specific Large Language Model
Loading search results
Construction of ARDS Clinical Multimodal Database and ARDS-Specific Large Language Model
Sponsor study identifier
observational
6,500
0 countries
N/A
Study Start
May 7, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this observational study is to integrate existing clinical cohorts from the research team to establish dedicated cohorts for ARDS and high-risk ARDS patients (primarily SCAP patients), then systematically collect comprehensive clinical data and multi-omics biological samples to construct a high-quality multimodal ARDS database. Building upon this foundation, the research will develop an ARDS-specific large-scale disease model to assist clinical decision-making in early warning, diagnosis, and prognosis prediction. The main question it seeks to address is: Can the establishment of specialized ARDS cohorts and multimodal databases, combined with the development of an ARDS-specific large-scale disease model, effectively improve ARDS prediction rates, diagnostic accuracy, and reduce mortality rates, thereby enhancing overall clinical management standards?
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1, 2025
Actual (reported)May 7, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 15, 2025
Actual (reported)December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
ICU mortality
From the time of patient enrollment until ICU discharge(For example: If a patient is enrolled in the study and remains in the ICU for 20 days before discharge, then the time frame would be 20 days.)
Hospital mortality
From the time of patient enrollment until hospital discharge(For example: If a patient is enrolled in the study and remains in the hospital for 20 days before discharge, then the observation time frame would be 20 days.)
ICU length of stay
From the time of patient enrollment until ICU discharge(For example: If a patient is enrolled in the study and remains in the ICU for 20 days before discharge, then the observation time frame would be 20 days.)
Hospital length of stay
From enrollment to hospital discharge(For example: If a patient is enrolled in the study and remains in the hospital for 20 days before discharge, then the observation time frame would be 20 days.)
Mortality rates at 28 days post-enrollment
From patient enrollment until 28 days post-enrollment
Mortality rates at 60 days post-enrollment
From patient enrollment until 60 days post-enrollment
Mortality rates at 90 days post-enrollment
From patient enrollment until 90 days post-enrollment
Patients meeting the 2024 global new definition of ARDS.
Patients admitted to the ICU who do not meet ARDS diagnostic criteria but present with established ARDS risk factors, including: SCAP,, sepsis, high-risk trauma, post high-risk surgery, acute pancreatitis, shock, and aspiration.The primary etiology in this cohort is SCAP.
Clinical Data Collection: Case report forms were utilized to systematically capture multimodal clinical data, including: demographic characteristics, clinical symptoms and physical signs, laboratory test results, chest imaging data, organ support parameters, pharmacological interventions , complications and clinical outcomes. Biospecimen Collection: ARDS patients underwent biospecimen collection at days 1, 4, and 7 post-diagnosis. High-risk ARDS cohorts provided specimens within 24 hours of ICU admission. Specimens included: peripheral blood, Sputum/BALF, stool and urine.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
1. ARDS ptients; 2. ARDS high-risk patients
First Submitted
April 1, 2025
First Posted
May 15, 2025
Study Start
May 7, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2027
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 15, 2025
Record last verified: 2025-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: